Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/5CF95067.svg?ark=w1%2F20260515%2F5CF95067)](https://nobleid.org/work/w1/20260515/5CF95067)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors